Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00468169 · ClinicalTrials.gov registry record · Phase 2
Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer
A Phase 2 study, sponsored by University of Chicago.
- Completed
- Registry status
- Phase 2
- Development phase
- 110
- Enrollment target
NCT00468169 is a Phase 2 study that has completed, run by University of Chicago. The registered enrollment target is 110 participants.
The verdict
NCT00468169, a Phase 2 study, has completed, sponsored by University of Chicago.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 110 participants
- Enrollment target
Study Summary
The main purpose of this study is to explore and compare the efficacy of Cetuximab (ERBITUX®) added to two concurrent chemoradiotherapy platforms of different intensity in locally advanced head and neck cancer.
Interventions
- DRUG Cisplatin
- DRUG Hydroxyurea
- DRUG Cetuximab
- DRUG 5-FU
- RADIATION Twice-daily radiation
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 110 participants |
| Start Date | 2006-07 |
| Est. Completion | 2012-11 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00468169
The ClinicalTrials.gov registry entry for NCT00468169 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 110 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Chicago, which has 796 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Cisplatin is the first listed.
NCT00468169 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00468169 about?
NCT00468169 is a clinical study titled "Cetuximab (ERBITUX®) Added to Two Concurrent Chemoradiotherapy Platforms in Locally Advanced Head and Neck Cancer". The main purpose of this study is to explore and compare the efficacy of Cetuximab (ERBITUX®) added to two concurrent chemoradiotherapy platforms of different intensity in locally advanced head and neck cancer.
What is the current status of trial NCT00468169?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 110 participants. The study started on 2006-07. Estimated completion is 2012-11.
What interventions are being tested in trial NCT00468169?
The interventions under investigation include: Cisplatin (DRUG), Hydroxyurea (DRUG), Cetuximab (DRUG), 5-FU (DRUG), Twice-daily radiation (RADIATION).
Who is sponsoring clinical trial NCT00468169?
This trial is sponsored by University of Chicago, which has 796 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.